After February market crash, ProQR will lay off 30% of its workforce and try pushing eye therapy after failed trial

Kyle LaHucik

Senior Reporter

A pivotal trial flop in February caused ProQR to lose nearly two-thirds of its stock value and that means the transatlantic company will officially join the dozens of biotechs and pharmas to lay off employees in the past few months.

ProQR will lay off 30% of its workforce, including chief scientific officer Naveed Shams, this quarter, the company said Wednesday. The Dutch-US biotech says it employs 160 people according to its careers page, and a spokesperson confirmed to Endpoints News that about 50 employees were affected.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

After February market crash, ProQR will lay off 30% of its workforce and try pushing eye therapy after failed trial

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Sanofi restructures US commercial vaccines sales force

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

Af­ter Feb­ru­ary mar­ket crash, Pro­QR will lay off 30% of its work­force and try push­ing eye ther­a­py af­ter failed tri­al

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

Sanofi re­struc­tures US com­mer­cial vac­cines sales force

His­to­gen files for bank­rupt­cy; Barinthus Bio shares Ph1b/2 da­ta for HPV treat­ment

After February market crash, ProQR will lay off 30% of its workforce and try pushing eye therapy after failed trial

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Sanofi restructures US commercial vaccines sales force

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment